Syros Pharmaceuticals (SYRS) Tops Q3 EPS by 3c; Reports Cash and Cash Equivalents of $166.7M

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/5/2026

1. NVDA
2. PCVX
3. SPY
4. PTC
5. MSFT
6. META
7. AMD
8. GMAB
9. AMZN
10. ATH

Go back to Syros Pharmaceuticals (SYRS) Tops Q3 EPS by 3c; Reports Cash and Cash Equivalents of $166.7M

Syros Reports Third Quarter 2021 Financial Results and Highlights Key Accomplishments and Upcoming Milestones

November 5, 2021 7:30 AM EDT

First Patient Dosed in SELECT-AML-1 Trial of Tamibarotene and in Dose Confirmation Study of SY-2101 in APL

Presented Phase 1 Data of SY-5609 at ESMO, Demonstrating Clinical Activity at Tolerable Doses and Supporting Development in Three Combination Regimens

Expanded Leadership Team with Key Appointments

Management to Host Conference Call at 8:30 a.m. ET Today

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today... More